DDrare: Database of Drug Development for Rare Diseases

22. もやもや病
［臨床試験数：11，薬物数：18（DrugBank：11），標的遺伝子数：28，標的パスウェイ数：43］

Searched query = "Moyamoya disease", "Occlusive disease in circle of Willis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Aspirin; Butylphthalide; Desflurane; Device: Magnetic Resonance Imaging; Device: RIC; Dl-3-n-butylphthalide (NBP); Edaravone; Erythropoietin; Gadobutrol; Gadovist; Norepinephrine; Normal Saline 0.9% Infusion Solution; Normal saline; Phenylephrine; Propofol; Sevoflurane; Xenon; Xenon contrast agent

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04205578 (ClinicalTrials.gov)	January 2020	18/12/2019	NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events	A Multi-center, Randomized, Single-blind, Placebo-controlled Study of Dl-3-n-butylphthalide in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events After Extracranial-to-intracranial Revascularization Surgery	Moyamoya Disease;Ischemic Cerebral Infarction;Ischemic Stroke;Ischemic Cerebrovascular Accident;Transient Ischemic Attack	Drug: dl-3-n-butylphthalide (NBP);Drug: Normal Saline 0.9% Infusion Solution	yuanli Zhao	Peking University International Hospital	Not yet recruiting	18 Years	60 Years	All	450	Phase 3	China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04205578
(ClinicalTrials.gov)

January 2020

18/12/2019

NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events

A Multi-center, Randomized, Single-blind, Placebo-controlled Study of Dl-3-n-butylphthalide in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events After Extracranial-to-intracranial Revascularization Surgery

Moyamoya Disease;Ischemic Cerebral Infarction;Ischemic Stroke;Ischemic Cerebrovascular Accident;Transient Ischemic Attack

Drug: dl-3-n-butylphthalide (NBP);Drug: Normal Saline 0.9% Infusion Solution

yuanli Zhao

Peking University International Hospital

Not yet recruiting

18 Years

60 Years

All

450

Phase 3

China